Dishman Carbogen Amcis Limited (DCAL.NS)
INR 275.77
(-2.7%)
INR 275.77
(-2.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 39.53 Billion INR | 8.51% |
| 2022 | 36.43 Billion INR | 17.98% |
| 2021 | 30.88 Billion INR | 17.62% |
| 2020 | 26.25 Billion INR | 5.68% |
| 2019 | 24.84 Billion INR | 27.46% |
| 2018 | 19.49 Billion INR | -5.79% |
| 2017 | 20.69 Billion INR | 16.28% |
| 2016 | 17.79 Billion INR | 16.42% |
| 2015 | 15.28 Billion INR | -2.71% |
| 2014 | 15.71 Billion INR | 14.1% |
| 2013 | 13.76 Billion INR | 9.26% |
| 2012 | 12.6 Billion INR | -5.0% |
| 2011 | 13.26 Billion INR | 10.27% |
| 2010 | 12.03 Billion INR | 19.35% |
| 2009 | 10.08 Billion INR | 2.37% |
| 2008 | 9.84 Billion INR | 7.03% |
| 2007 | 9.2 Billion INR | 9.21% |
| 2006 | 8.42 Billion INR | 106.98% |
| 2005 | 4.07 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -56.27 Billion INR | -242.33% |
| 2023 FY | 39.53 Billion INR | 8.51% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 39.53 Billion INR | 0.0% |
| 2023 Q2 | 37.3 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 36.43 Billion INR | 0.0% |
| 2022 FY | 36.43 Billion INR | 17.98% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 32.72 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 30.88 Billion INR | 0.0% |
| 2021 Q2 | 27.35 Billion INR | 0.0% |
| 2021 FY | 30.88 Billion INR | 17.62% |
| 2020 Q4 | 26.25 Billion INR | 0.0% |
| 2020 Q2 | 23.73 Billion INR | 0.0% |
| 2020 FY | 26.25 Billion INR | 5.68% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 FY | 24.84 Billion INR | 27.46% |
| 2019 Q4 | 24.84 Billion INR | 0.0% |
| 2019 Q2 | 22.93 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 19.49 Billion INR | 0.0% |
| 2018 FY | 19.49 Billion INR | -5.79% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 22.92 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 20.69 Billion INR | 16.28% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 18.39 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 20.69 Billion INR | 0.0% |
| 2016 Q2 | 14.08 Billion INR | 0.0% |
| 2016 FY | 17.79 Billion INR | 16.42% |
| 2016 Q4 | 17.79 Billion INR | 0.0% |
| 2015 Q4 | 15.28 Billion INR | 0.0% |
| 2015 FY | 15.28 Billion INR | -2.71% |
| 2015 Q2 | 15.06 Billion INR | 0.0% |
| 2014 Q2 | 14.23 Billion INR | 0.0% |
| 2014 FY | 15.71 Billion INR | 14.1% |
| 2014 Q4 | 15.71 Billion INR | 0.0% |
| 2013 Q2 | 14.34 Billion INR | 0.0% |
| 2013 Q4 | 13.76 Billion INR | 0.0% |
| 2013 FY | 13.76 Billion INR | 9.26% |
| 2012 Q4 | 12.6 Billion INR | 0.0% |
| 2012 FY | 12.6 Billion INR | -5.0% |
| 2011 FY | 13.26 Billion INR | 10.27% |
| 2011 Q4 | 13.26 Billion INR | 0.0% |
| 2010 FY | 12.03 Billion INR | 19.35% |
| 2009 FY | 10.08 Billion INR | 2.37% |
| 2008 FY | 9.84 Billion INR | 7.03% |
| 2007 FY | 9.2 Billion INR | 9.21% |
| 2006 FY | 8.42 Billion INR | 106.98% |
| 2005 FY | 4.07 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biocon Limited | 307.95 Billion INR | 87.161% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | -1750.854% |
| Concord Biotech Limited | 1.74 Billion INR | -2171.505% |
| Jubilant Ingrevia Limited | 19.94 Billion INR | -98.246% |
| Lyka Labs Limited | 884.58 Million INR | -4369.713% |
| Panacea Biotec Limited | 4.02 Billion INR | -883.496% |
| Piramal Pharma Limited | 74 Billion INR | 46.573% |
| SMS Lifesciences India Limited | 1.96 Billion INR | -1908.226% |
| Supriya Lifescience Limited | 1.05 Billion INR | -3634.627% |
| Syngene International Limited | 18.93 Billion INR | -108.768% |
| TAKE Solutions Limited | 969.78 Million INR | -3977.059% |
| Zota Health Care Limited | 1.38 Billion INR | -2757.821% |